GlassScriptPhysician profile
Samantha E Steinberg
NPI 1598328742
$4,192.91
in general payments reported to CMS, 2019-2025
33 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $192 · 2023: $1,125 · 2024: $1,439 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.71 |
| Education | $202.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $635.73 | 2022-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $457.37 | 2023-2025 | |
| Lilly USA, LLC | $381.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $354.23 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $266.24 | 2023-2025 | Gemtesa, Myfembree |
| Otsuka America Pharmaceutical, INC. | $239.41 | 2023-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $209.25 | 2022-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $184.51 | 2024 | Veozah |
| Radius Health, INC. | $176.25 | 2023-2025 | Tymlos |
| Glaxosmithkline, LLC. | $172.00 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Intuitive Surgical, INC. | $122.50 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.11 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $101.71 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $100.40 | 2022-2025 | |
| Lundbeck LLC | $59.99 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.25 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $52.78 | 2025 | |
| Shield Therapeutics INC | $49.71 | 2025 | |
| Sanofi Pasteur INC. | $48.89 | 2025 | |
| Novo Nordisk INC | $48.75 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Seqirus USA INC | $41.38 | 2024-2025 | Flucelvax, Fluad |
| Boston Scientific Corporation | $37.18 | 2023 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $37.06 | 2024-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $36.53 | 2024 | Austedo Xr |
| Abbvie INC. | $34.00 | 2022-2023 | Ubrelvy |
| Edwards Lifesciences Corporation | $33.36 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.51 | 2023-2024 | Xarelto |
| Hologic Sales and Service, LLC | $22.98 | 2025 | Aptima |
| Kowa Pharmaceuticals America, INC. | $20.74 | 2023 | Livalo, Seglentis |
| Bausch Health US, LLC | $18.03 | 2022 | |
| Abiomed | $17.26 | 2023 | Impella |
| Medtronic, INC. | $17.24 | 2025 | Interstim |
| Dexcom, INC. | $14.00 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.